ストックスクリーナーアプリを入手
2.14
3.38%
0.07
アフターアワーズ：
2.15
0.010
+0.47%
前日終値:
$2.07
開ける：
$2.09
24時間の取引高:
532.14K
Relative Volume:
0.33
時価総額：
$207.40M
収益：
$20.76M
当期純損益:
$-132.49M
株価収益率:
-0.8015
EPS:
-2.67
ネットキャッシュフロー:
$-108.55M
1週間 パフォーマンス:
-1.83%
1か月 パフォーマンス:
+0.94%
6か月 パフォーマンス:
-5.31%
1年 パフォーマンス:
-40.88%
1日の値動き範囲:
$2.0809
$2.146
1週間の範囲:
$2.06
$2.23
52週間の値動き範囲:
$1.085
$3.84
C 4 Therapeutics Inc Stock (CCCC) Company Profile
CCCC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.14 | 200.61M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-02 | 開始されました | TD Cowen | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-15 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Equal-Weight |
| 2024-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-12-13 | アップグレード | Stifel | Hold → Buy |
| 2023-02-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-04-28 | 開始されました | Credit Suisse | Underperform |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-10 | 開始されました | JP Morgan | Overweight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-11-23 | 開始されました | BofA Securities | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-27 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-27 | 開始されました | Jefferies | Buy |
すべてを表示
C 4 Therapeutics Inc (CCCC) 最新ニュース
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New C4 Therapeutics hire granted options on 85,480 shares - Stock Titan
Volume Report: Is FAMI a good ESG investmentQuarterly Profit Review & Smart Money Movement Alerts - baoquankhu1.vn
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
FY2028 EPS Forecast for C4 Therapeutics Reduced by Analyst - MarketBeat
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock By Investing.com - Investing.com Australia
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock - Investing.com
Insider Sell: Leonard Reyno Sells Shares of C4 Therapeutics Inc (CCCC) - GuruFocus
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
Leonard Reyno Sells 10,000 Shares of C4 Therapeutics (NASDAQ:CCCC) Stock - MarketBeat
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Aug Intraday: Is Coincheck Group NV stock good for income investorsJuly 2025 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors - TipRanks
C4 Therapeutics to advance cemsidomide trials for multiple myeloma By Investing.com - Investing.com Nigeria
C4 Therapeutics (CCCC) Announces Ambitious Milestones Through 20 - GuruFocus
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways - Investing News Network
C4 Therapeutics to advance cemsidomide trials for multiple myeloma - Investing.com
C4 Therapeutics Outlines Strategic Milestones for Cemsidomide - TradingView
C4 Therapeutics Advances Cemsidomide Trials and Internal Discovery Strategy Ahead of Key Milestones Through 2028 - Quiver Quantitative
Potential multiple myeloma drug from C4 Therapeutics plans trials to 2028 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch - TipRanks
How C4 Therapeutics Inc. stock performs in weak economy - Улправда
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Is C4 Therapeutics Inc. stock trading at a premium valuationWeekly Trend Recap & Smart Swing Trading Techniques - Улправда
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
Is C4 Therapeutics Inc. stock in correction or buying zoneJuly 2025 Big Picture & Safe Swing Trade Setups - Улправда
Is C4 Therapeutics Inc. stock oversold or undervaluedMarket Growth Review & Accurate Entry/Exit Alerts - Улправда
How C4 Therapeutics Inc. stock benefits from tech adoptionQuarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Is C4 Therapeutics (CCCC) one of the best biotech penny stocks to buy according to analysts? - MSN
Market Rankings: Is C4 Therapeutics Inc stock oversold or undervaluedQuarterly Portfolio Review & Breakout Confirmation Alerts - moha.gov.vn
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
C4 Therapeutics, Inc.Common Stock (NQ: CCCC - FinancialContent
Brookline Capital Management Estimates C4 Therapeutics FY2030 Earnings - MarketBeat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
C 4 Therapeutics Inc (CCCC) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):